SML1960

GSK583

≥98% (HPLC)

• Synonim(y): GSK583, 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine, GSK′583, GSK-2616583A
• Wzór empiryczny (zapis Hilla): C₂₀H₁₉FN₄O₂S
• Numer CAS: 1346547-00-9
• Masa cząsteczkowa: 398.45
• Kod UNSPSC: 51111800
• NACRES: NA.77

Właściwości

• Poziom jakości: 100
• Próba: ≥98% (HPLC)
• Formularz: powder
• warunki przechowywania: desiccated; protect from light
• kolor: white to beige
• rozpuszczalność: DMSO: 20 mg/mL, clear
• temp. przechowywania: 2-8°C
• ciąg SMILES: Fc1cc2c([nH]nc2Nc3c4c(ncc3)ccc(c4)[S](=O)(=O)C(C)(C)C)cc1
• Klucz InChI: XLOGLWKOHPIJLV-UHFFFAOYSA-N

Opis

Działania biochem./fizjol.

An ATP-competitive RIP2 (RIPK2) inhibitor with in vitro and in vivo efficacy against NOD1- and NOD2-dependent pro-inflammatory cytokines release.

GSK583 is a cell-permeable indazolylquinolinamine that acts as an ATP-competitive (IC50 = 2 & 5 nM using rat & human RIPK2, respectively) inhibitor against RIPK2 kinase activity (66.6% inhibition at 1 μM; [ATP] = 10 μM), exhibiting much reduced or no inhibitory potency against a panel of 209 other kinases <34% inhibition at 1 μM; [ATP] = 10 ?M). GSK583 selectively inhibits against NOD1- and NOD2-, but not TLR2-, TLR4-, TLR7-. IL-1R-, or TNFR-dependent pro-inflammatory cytokines release (>95% inhibition vs. <40% inhibition at 1 ?M using primary human monocytes stimulated with respective ligands). GSK583 effectively inhibits TNF? and IL-6 production from Crohn′s disease (CD) and ulcerative colitis (UC) patients intestinal explant cultures ex vivo (IC50 = 200 nM) and is efficacious against NOD1 ligand FK156- and NOD2 ligand MDP-induced inflammatory responses in mice and rats (10 mg/kg p.o.) in vivo.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable